Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Antiparkinsonian drugs anticholinergic)
3,701 results
  • Delirium secondary to anticholinergics. [Case Reports]
    BMJ Case Rep. 2023 Jan 10; 16(1)Bellizzi A, Mercieca E, Dimech C
  • We present a case of a young man who developed sudden deterioration in his physical and mental state whilst being treated as an inpatient for substance-induced psychosis. This deterioration was manifested by sudden disorientation, change in behaviour and visual hallucinations. It was only after excluding other potential causes that this presentation was attributed to the regular administration of…
  • Case series profile of olanzapine post-injection delirium/sedation syndrome. [Journal Article]
    Br J Clin Pharmacol. 2023 Feb; 89(2):903-907.Seebaluck J, Downes MA, … Chan BS
  • Olanzapine pamoate is an intramuscular depot injection for the treatment of schizophrenia. Approximately 1.4% of patients develop a serious adverse event called post-injection delirium/sedation syndrome (PDSS), characterised by drowsiness, anticholinergic and extrapyramidal symptoms. The objective is to investigate olanzapine PDSS presentations including clinical features and treatment approach. …
  • Tremor in Parkinson's Disease: From Pathophysiology to Advanced Therapies. [Review]
    Tremor Other Hyperkinet Mov (N Y). 2022; 12:29.Abusrair AH, Elsekaily W, Bohlega S
  • Tremor is one of the most prevalent symptoms in Parkinson's Disease (PD). The progression and management of tremor in PD can be challenging, as response to dopaminergic agents might be relatively poor, particularly in patients with tremor-dominant PD compared to the akinetic/rigid subtype. In this review, we aim to highlight recent advances in the underlying pathogenesis and treatment modalities …
  • Cholinergic models of memory impairment in animals and man: scopolamine vs. biperiden. [Journal Article]
    Behav Pharmacol. 2022 06 01; 33(4):231-237.Blokland A
  • Scopolamine has been used as a pharmacologic model for cognitive impairments in dementia and Alzheimer's disease. The validity of this model seems to be limited because findings in animals do not readily translate to novel treatments in humans. Biperiden is also a cholinergic deficit model for cognitive impairments but specifically blocks muscarinic M1 receptors. The effects of scopolamine and bi…
  • The Role of the Microbiota-Gut-Brain Axis in the Development of Alzheimer's Disease. [Review]
    Int J Mol Sci. 2022 Apr 27; 23(9)Wiatrak B, Balon K, … Szeląg A
  • Along with the increase in life expectancy in the populations of developed and developing countries resulting from better access and improved health care, the number of patients with dementia, including Alzheimer's disease (AD), is growing. The disease was first diagnosed and described at the beginning of the 20th century. However, to this day, there is no effective causal therapy, and symptomati…
New Search Next